Quantcast
Home > Quotes > NVLN

Novelion Therapeutics Inc. Common Shares (NVLN) Quote & Summary Data

NVLN 
$1.34
*  
0.04
2.9%
Get NVLN Alerts
*Delayed - data as of Apr. 18, 2019  -  Find a broker to begin trading NVLN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
$ 1.3928 / $ 1.32
Share Volume
45,250
50 Day Avg. Daily Volume
197,946
Previous Close
$ 1.38
52 Week High / Low
$ 4.7895 / $ 0.70
Market Cap
24,834,259
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -5.78
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.26

Intraday Chart

Shares Traded

Share Volume:
45,250
50 Day Avg. Daily Volume:
197,946

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -5.78

Trading Range

The current last sale of $1.34 is 91.43% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.3928 $ 4.7895
 Low: $ 1.32 $ 0.70

Company Description (as filed with the SEC)

We are a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. As described below, we, through our subsidiary Aegerion, develop and commercialize two rare disease products, metreleptin and lomitapide. During the year ended December 31, 2018, net revenues from metreleptin and lomitapide were $130.4 million, of which $83.4 million was derived from prescriptions for metreleptin and lomitapide written in the U.S., and $47.0 million was derived from prescriptions written for and royalties on sales of metreleptin and lomitapide outside the U.S. As of December 31, 2018, we had approximately $45.2 million in cash and cash equivalents, of which $31.9 million was held and controlled by our subsidiary Aegerion.  ... More ...  



Risk Grade

Where does NVLN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.36
Open Date:
Apr. 18, 2019
Close Price:
$ 1.34
Close Date:
Apr. 18, 2019


Consensus Recommendation

Analyst Info